Summary of Study ST003181

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001980. The data can be accessed directly via it's Project DOI: 10.21228/M8SJ0J This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003181
Study TitleDepression symptoms modifies differently plasma metabolites in pre- and post-menopausal women
Study SummaryDepression will be the disease with the highest incidence worldwide by 2030. Data indicate that postmenopausal women have a higher incidence of mood disorders, and this high vulnerability seems to be related to hormonal changes and weight gain. Although research evaluating the profile of metabolites in mood disorders is advancing, further research, maintaining consistent methodology, is necessary to reach a consensus. Therefore, the objective of the present study was to carry out an exploratory analysis of the plasma polar metabolites and lipids of pre- and postmenopausal women to explore whether the profile is affected by depression. The study was performed in accordance with the principles of the Declaration of Helsinki and was approved by the Human Research Ethics Committee of the Universidade Federal de São Paulo (nº 0624/2019) and all participants signed the informed consent. 42 premenopausal and 67 postmenopausal women had the depression symptoms assessed by the Beck Depression's Inventory (BDI). Lipids and polar metabolites were extracted from plasma and analyzed in an ultra-performance liquid chromatography system (UHPLC) coupled to a spectrometer with a triple-quadrupole analyzer operating with an electrospray ionization source (ESI) in positive and negative mode. Lipids and polar metabolites analyses was performed using MetaboAnalyst 5.0. Ten metabolites were significantly affected by depression symptoms in postmenopause, including Adenosine, Guanosine, Proline, Citrulline, Lysine, and Carnitine, which were down-regulated, and Dimethylglycine, Glutathione, Creatine, and Methionine that were up-regulated. In premenopausal women with depression, Oxidized Glutathione was down-regulated, and Dimethylglycine and 4-hydroxyproline were up-regulated. Seven lipids were were significantly affected by depression symptoms in pre-menopausal women PC(36:1)/PC(18:1(9Z)/18:0), PC(19:0/19:0), and LTB4 were up-regulated and PC(18:0/14:0)/GPCho(18:0/14:0), SM(d18:1/16:0), LysoPC(18:1(9z))/LPC 18:1, and Azelaoyl-PAF were down-regulated. In post-menopausal women PC(16:1(9z)/16:1(9z)) and 14,15-DHET were down-regulated and acetylcarnitine was up-regulated. Though there seems to be a relationship in the occurrence of obesity and depression in women the hormonal status influenced the effect of depression in women and that this status may be taken into account when searching for a marker for depression.
Institute
Federal University of São Paulo
Last NameBoldarine
First NameValter
AddressRua Botucatu, 862, 2º floor, São Paulo, São Paulo, 04026-000, Brazil
Emailvaltertadeuboldarine@gmail.com
Phone(11) 99892-8283
Submit Date2024-04-11
Raw Data AvailableYes
Raw Data File Type(s)mzML
Analysis Type DetailLC-MS
Release Date2024-05-17
Release Version1
Valter Boldarine Valter Boldarine
https://dx.doi.org/10.21228/M8SJ0J
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001980
Project DOI:doi: 10.21228/M8SJ0J
Project Title:Depression symptoms modifies differently plasma metabolites in pre- and post-menopausal women
Project Summary:Depression will be the disease with the highest incidence worldwide by 2030. Data indicate that postmenopausal women have a higher incidence of mood disorders, and this high vulnerability seems to be related to hormonal changes and weight gain. Although research evaluating the profile of metabolites in mood disorders is advancing, further research, maintaining consistent methodology, is necessary to reach a consensus. Therefore, the objective of the present study was to carry out an exploratory analysis of the plasma polar metabolites and lipids of pre- and postmenopausal women to explore whether the profile is affected by depression. The study was performed in accordance with the principles of the Declaration of Helsinki and was approved by the Human Research Ethics Committee of the Universidade Federal de São Paulo (nº 0624/2019) and all participants signed the informed consent. 42 premenopausal and 67 postmenopausal women had the depression symptoms assessed by the Beck Depression's Inventory (BDI). Lipids and polar metabolites were extracted from plasma and analyzed in an ultra-performance liquid chromatography system (UHPLC) coupled to a spectrometer with a triple-quadrupole analyzer operating with an electrospray ionization source (ESI) in positive and negative mode. Lipids and polar metabolites analyses was performed using MetaboAnalyst 5.0. Ten metabolites were significantly affected by depression symptoms in postmenopause, including Adenosine, Guanosine, Proline, Citrulline, Lysine, and Carnitine, which were down-regulated, and Dimethylglycine, Glutathione, Creatine, and Methionine that were up-regulated. In premenopausal women with depression, Oxidized Glutathione was down-regulated, and Dimethylglycine and 4-hydroxyproline were up-regulated. Seven lipids were were significantly affected by depression symptoms in pre-menopausal women PC(36:1)/PC(18:1(9Z)/18:0), PC(19:0/19:0), and LTB4 were up-regulated and PC(18:0/14:0)/GPCho(18:0/14:0), SM(d18:1/16:0), LysoPC(18:1(9z))/LPC 18:1, and Azelaoyl-PAF were down-regulated. In post-menopausal women PC(16:1(9z)/16:1(9z)) and 14,15-DHET were down-regulated and acetylcarnitine was up-regulated. Though there seems to be a relationship in the occurrence of obesity and depression in women the hormonal status influenced the effect of depression in women and that this status may be taken into account when searching for a marker for depression.
Institute:Universidade Federal de São Paulo
Last Name:Boldarine
First Name:Valter
Address:Rua Botucatu, 862, 2º floor, São Paulo, São Paulo, 04026-000, Brazil
Email:valtertadeuboldarine@gmail.com
Phone:(11) 99892-8283

Subject:

Subject ID:SU003300
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Gender:Female

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sample source Condition Symptom
SA34631220210111_ML_Branco- - -
SA34631320210111_ML_Branco+PIM- - -
SA34631420210111_ML_85Plasma Postmenopause Control
SA34631520210111_ML_86Plasma Postmenopause Control
SA34631620210111_ML_89Plasma Postmenopause Control
SA34631720210111_ML_82Plasma Postmenopause Control
SA34631820210111_ML_80Plasma Postmenopause Control
SA34631920210111_ML_67Plasma Postmenopause Control
SA34632020210111_ML_68Plasma Postmenopause Control
SA34632120210111_ML_76Plasma Postmenopause Control
SA34632220210111_ML_92Plasma Postmenopause Control
SA34632320210111_ML_94Plasma Postmenopause Control
SA34632420210111_ML_101Plasma Postmenopause Control
SA34632520210111_ML_103Plasma Postmenopause Control
SA34632620210111_ML_104Plasma Postmenopause Control
SA34632720210111_ML_100Plasma Postmenopause Control
SA34632820210111_ML_97Plasma Postmenopause Control
SA34632920210111_ML_66Plasma Postmenopause Control
SA34633020210111_ML_109Plasma Postmenopause Control
SA34633120210111_ML_106Plasma Postmenopause Control
SA34633220210111_ML_53Plasma Postmenopause Control
SA34633320210111_MP_104Plasma Postmenopause Control
SA34633420210111_MP_106Plasma Postmenopause Control
SA34633520210111_MP_109Plasma Postmenopause Control
SA34633620210111_MP_112Plasma Postmenopause Control
SA34633720210111_MP_103Plasma Postmenopause Control
SA34633820210111_MP_101Plasma Postmenopause Control
SA34633920210111_MP_94Plasma Postmenopause Control
SA34634020210111_MP_97Plasma Postmenopause Control
SA34634120210111_MP_100Plasma Postmenopause Control
SA34634220210111_MP_114Plasma Postmenopause Control
SA34634320210111_MP_115Plasma Postmenopause Control
SA34634420210111_MP_147Plasma Postmenopause Control
SA34634520210111_ML_51Plasma Postmenopause Control
SA34634620210111_ML_112Plasma Postmenopause Control
SA34634720210111_MP_144Plasma Postmenopause Control
SA34634820210111_MP_134Plasma Postmenopause Control
SA34634920210111_MP_116Plasma Postmenopause Control
SA34635020210111_MP_119Plasma Postmenopause Control
SA34635120210111_MP_123Plasma Postmenopause Control
SA34635220210111_ML_62Plasma Postmenopause Control
SA34635320210111_ML_116Plasma Postmenopause Control
SA34635420210111_LC_103Plasma Postmenopause Control
SA34635520210111_LC_104Plasma Postmenopause Control
SA34635620210111_LC_106Plasma Postmenopause Control
SA34635720210111_LC_101Plasma Postmenopause Control
SA34635820210111_LC_100Plasma Postmenopause Control
SA34635920210111_LC_92Plasma Postmenopause Control
SA34636020210111_LC_94Plasma Postmenopause Control
SA34636120210111_LC_97Plasma Postmenopause Control
SA34636220210111_LC_109Plasma Postmenopause Control
SA34636320210111_LC_112Plasma Postmenopause Control
SA34636420210111_LC_134Plasma Postmenopause Control
SA34636520210111_LC_144Plasma Postmenopause Control
SA34636620210111_LC_147Plasma Postmenopause Control
SA34636720210111_LC_123Plasma Postmenopause Control
SA34636820210111_LC_119Plasma Postmenopause Control
SA34636920210111_LC_114Plasma Postmenopause Control
SA34637020210111_LC_115Plasma Postmenopause Control
SA34637120210111_LC_116Plasma Postmenopause Control
SA34637220210111_LC_89Plasma Postmenopause Control
SA34637320210111_LC_86Plasma Postmenopause Control
SA34637420210111_ML_144Plasma Postmenopause Control
SA34637520210111_ML_147Plasma Postmenopause Control
SA34637620210111_LC_51Plasma Postmenopause Control
SA34637720210111_ML_134Plasma Postmenopause Control
SA34637820210111_ML_123Plasma Postmenopause Control
SA34637920210111_ML_115Plasma Postmenopause Control
SA34638020210111_MP_92Plasma Postmenopause Control
SA34638120210111_ML_119Plasma Postmenopause Control
SA34638220210111_LC_53Plasma Postmenopause Control
SA34638320210111_LC_62Plasma Postmenopause Control
SA34638420210111_LC_80Plasma Postmenopause Control
SA34638520210111_LC_82Plasma Postmenopause Control
SA34638620210111_LC_85Plasma Postmenopause Control
SA34638720210111_LC_76Plasma Postmenopause Control
SA34638820210111_LC_71Plasma Postmenopause Control
SA34638920210111_LC_66Plasma Postmenopause Control
SA34639020210111_LC_67Plasma Postmenopause Control
SA34639120210111_LC_68Plasma Postmenopause Control
SA34639220210111_ML_114Plasma Postmenopause Control
SA34639320210111_ML_71Plasma Postmenopause Control
SA34639420210111_MP_80Plasma Postmenopause Control
SA34639520210111_MP_82Plasma Postmenopause Control
SA34639620210111_MP_66Plasma Postmenopause Control
SA34639720210111_MP_76Plasma Postmenopause Control
SA34639820210111_MP_71Plasma Postmenopause Control
SA34639920210111_MP_51Plasma Postmenopause Control
SA34640020210111_MP_67Plasma Postmenopause Control
SA34640120210111_MP_53Plasma Postmenopause Control
SA34640220210111_MP_85Plasma Postmenopause Control
SA34640320210111_MP_62Plasma Postmenopause Control
SA34640420210111_MP_68Plasma Postmenopause Control
SA34640520210111_MP_89Plasma Postmenopause Control
SA34640620210111_MP_86Plasma Postmenopause Control
SA34640720210111_ML_90Plasma Postmenopause Depression
SA34640820210111_ML_91Plasma Postmenopause Depression
SA34640920210111_MP_55Plasma Postmenopause Depression
SA34641020210111_MP_56Plasma Postmenopause Depression
SA34641120210111_ML_55Plasma Postmenopause Depression
Showing page 1 of 5     Results:    1  2  3  4  5  Next     Showing results 1 to 100 of 401

Collection:

Collection ID:CO003293
Collection Summary:Blood samples were colected after 12 hours overnight fast and centrifuged 20 min, 3000 RPM, 4ºC
Sample Type:Blood (plasma)

Treatment:

Treatment ID:TR003309
Treatment Summary:No treatment. Analyses of pre- and post-menopause women with or without depressive symptons

Sample Preparation:

Sampleprep ID:SP003307
Sampleprep Summary:Aliquots of 50 µL of plasma were added into a 96-deep well plate cell to which 1 µL of thiol-derivatization solution (200 mM N-ethylmaleimide (NEM) + 2 mM citric acid) was added. Subsequently, 200 µL of precipitation solution (acetonitrile/isopropanol (7:3, v/v) + 1% formic acid + isotopically labelled internal standards) were added. After vortex agitation for 10 min. and refrigeration at -20ºC for 10 minutes, the samples were centrifuged (14.000 rpm for 10 minutes at 4°C).

Combined analysis:

Analysis ID AN005225
Analysis type MS
Chromatography type Reversed phase
Chromatography system Shimadzu Nexera X2
Column Merck Discovery HS F5 (PFP) (150 x 2.1mm,3um)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name Shimadzu LCMS-IT-TOF
Ion Mode UNSPECIFIED
Units Peak area

Chromatography:

Chromatography ID:CH003952
Chromatography Summary:Shimadzu Nexera X2 was used for chromatography, whereas Shimadzu LCMS-IT-TOF was used for MS runs
Instrument Name:Shimadzu Nexera X2
Column Name:Merck Discovery HS F5 (PFP) (150 x 2.1mm,3um)
Column Temperature:40ºC
Flow Gradient:from 100% A to 5% A in 15 min., maintained 5% A for 5 min
Flow Rate:0.25 mL/min for 20 minutes
Solvent A:100% water; 0.1% formic acid
Solvent B:100% acetonitrile; 0.1% formic acid
Chromatography Type:Reversed phase

MS:

MS ID:MS004958
Analysis ID:AN005225
Instrument Name:Shimadzu LCMS-IT-TOF
Instrument Type:Triple quadrupole
MS Type:ESI
MS Comments:polarity switching was used
Ion Mode:UNSPECIFIED
  logo